Abstract:
:As in all patient populations, epilepsy is common in pregnant women. Consequently, approximately 1 in 200 pregnancies is exposed to antiepileptic drugs (AEDs). Although exposure to AEDs in utero has been associated with an increased risk of major fetal malformations, most women with epilepsy require medication throughout pregnancy, since seizures themselves may be potentially harmful not only for the mother but also for the developing fetus. Physiological changes during pregnancy result in a reduction in the serum concentrations of most AEDs, particularly in late pregnancy. Changes in protein binding lead to a greater reduction in total than free (active) drug concentrations. Pharmacokinetic changes in pregnancy show interindividual variability and are not well understood for most newer AEDs. However, recent studies have shown that changes in lamotrigine clearance are particularly marked, with increases in each trimester and a significant fall in plasma concentrations, leading to consequent breakthrough seizures in some women. Concentrations may then rise precipitously after delivery, leading to symptoms of lamotrigine toxicity. Therapeutic drug monitoring could theoretically guide adjustment of AED dosage to achieve good seizure control while minimising fetal exposure, although there are several limitations to such monitoring. Firstly, there are wide interindividual variations in serum drug concentrations, with seizure control often correlating poorly with a given therapeutic range. Secondly, therapeutic ranges have not been well defined for newer AEDs and their measurement is often not always available. Thirdly, for highly protein-bound drugs, although measurement of free drug concentrations may more accurately reflect drug availability during pregnancy than total drug concentrations, assays for this are not always available and may be unreliable. Thus, it may be useful, prior to pregnancy, to establish the total and free drug concentrations required to achieve optimal seizure control in a given individual. Regular monitoring of AEDs has been advocated in each trimester and shortly after delivery, with adjustment of dosage to avoid seizure precipitation during pregnancy or symptoms of toxicity after birth. More frequent monitoring has been recommended for lamotrigine. However, aggressive drug monitoring of any AED has yet to be proven to be effective in improving seizure control or care. Furthermore, higher doses may be associated with a greater potential for teratogenicity and it is not yet known whether longer term adverse effects may be related to in utero exposure in the latter half of pregnancy. There is limited evidence about the relationship of maternal serum drug concentrations and teratogenicity. While there is a theoretical role for therapeutic drug monitoring in improving the risk-to-benefit ratio of AED therapy during pregnancy, there are many practical limitations. Future work is needed to clarify its role in improving seizure control during pregnancy and identifying serum drug concentrations that may be considered safe for fetal exposure.
journal_name
CNS Drugsjournal_title
CNS drugsauthors
Adab Ndoi
10.2165/00023210-200620100-00001subject
Has Abstractpub_date
2006-01-01 00:00:00pages
791-800issue
10eissn
1172-7047issn
1179-1934pii
20101journal_volume
20pub_type
杂志文章,评审相关文献
CNS DRUGS文献大全abstract:BACKGROUND:The introduction of second-generation antipsychotics (SGAs) over the past 2 decades generated considerable optimism that better antipsychotic treatments for schizophrenia and bipolar disorder were possible. SGAs offer several tolerability benefits over first-generation antipsychotics (FGAs), particularly wit...
journal_title:CNS drugs
pub_type: 杂志文章,meta分析,评审
doi:10.2165/11634500-000000000-00000
更新日期:2012-09-01 00:00:00
abstract::Despite the established efficacy of chimeric antigen receptor (CAR) T-cell therapy in hematologic malignancies, translating CAR T therapy to solid tumors has remained investigational. Glioblastoma, the most aggressive and lethal form of primary brain tumor, has recently been among the malignancies being trialed clinic...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-019-00687-3
更新日期:2020-02-01 00:00:00
abstract::A number of news items and case reports describing complex behaviours (e.g. sleep driving, sleep cooking, sleep eating, sleep conversations, sleep sex) associated with the use of hypnosedative medications have recently received considerable attention. Regulatory agencies examining these reports have subsequently issue...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/0023210-200822120-00005
更新日期:2008-01-01 00:00:00
abstract::The circadian rhythm of pineal melatonin secretion, which is controlled by the suprachiasmatic nucleus (SCN), is reflective of mechanisms that are involved in the control of the sleep/wake cycle. Melatonin can influence sleep-promoting and sleep/wake rhythm-regulating actions through the specific activation of MT(1) (...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200721120-00004
更新日期:2007-01-01 00:00:00
abstract:BACKGROUND:Walking impairment is a hallmark of multiple sclerosis (MS). It affects > 90% of individuals over time, reducing independence and negatively impacting health-related quality of life, productivity, and daily activities. Walking impairment is consistently reported as one of the most distressing impairments by ...
journal_title:CNS drugs
pub_type: 杂志文章,多中心研究,随机对照试验
doi:10.1007/s40263-018-0586-5
更新日期:2019-01-01 00:00:00
abstract:OBJECTIVES:Atomoxetine is commonly used to treat attention-deficit hyperactivity disorder (ADHD) in children with a broad range of cognitive abilities. We examined the association between level of cognitive functioning as determined by IQ and clinical response during treatment with atomoxetine. METHODS:The records of ...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11590450-000000000-00000
更新日期:2011-06-01 00:00:00
abstract::Alzheimer's disease (AD) is the most prevalent dementia in the world. Its cause(s) are presently largely unknown. The most common explanation for AD, now, is the amyloid cascade hypothesis, which states that the cause of AD is senile plaque formation by the amyloid β peptide, and the formation of neurofibrillary tangl...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-020-00737-1
更新日期:2020-07-01 00:00:00
abstract::Lisdexamfetamine dimesylate (lisdexamfetamine) is a long-acting amfetamine prodrug with a convenient once-daily oral regimen that offers the potential for improved adherence and reduced abuse compared with short-acting preparations of amfetamines. Lisdexamfetamine (as Elvanse Adult(®); Tyvense Adult™) has been approve...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-016-0327-6
更新日期:2016-04-01 00:00:00
abstract::Benzodiazepine hypnotic agents were the mainstream pharmacotherapy for insomnia from the 1960s to the 1980s, but their safety profile proved to be not quite as perfect as originally expected with regard to daytime performance and cognition, and above all the risk of dependence. These risks are substantially diminished...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418001-00005
更新日期:2004-01-01 00:00:00
abstract::Major depressive disorder (MDD) is a chronic, recurrent mental disease that causes serious disability. Because currently available antidepressants have limited efficacy with respect to response and remission in patients with MDD, clinicians must choose the best available treatment interventions for patients who do not...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-012-0032-z
更新日期:2013-05-01 00:00:00
abstract::New formulations of stimulant medications for the treatment of attention-deficit hyperactivity disorder (ADHD) have been an important focus for pharmaceutical industry research and development over the past decade. In this article, we review and assess the therapeutic potential of five new stimulant formulations (one ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200418140-00005
更新日期:2004-01-01 00:00:00
abstract:BACKGROUND:Although levodopa is considered the most effective pharmacotherapy for motor symptoms of Parkinson's disease (PD), chronic use is associated with motor complications, including fluctuating response and unpredictable, involuntary movements called dyskinesia. ADS-5102 (amantadine) extended-release (ER) capsule...
journal_title:CNS drugs
pub_type: 杂志文章,随机对照试验
doi:10.1007/s40263-018-0498-4
更新日期:2018-04-01 00:00:00
abstract::Risperidone (Risperdal), a psychotropic atypical antipsychotic agent, is thought to act via dopamine D(2) and serotonin 5-HT(2A) receptor antagonism. The clinical efficacy of oral risperidone in the treatment of bipolar mania and schizophrenia in adult patients is well established. In the US, risperidone is also appro...
journal_title:CNS drugs
pub_type: 评论,杂志文章
doi:10.2165/00023210-200822030-00006
更新日期:2008-01-01 00:00:00
abstract::Epileptic encephalopathy is defined as a condition where the epileptic activity itself may contribute to the severe neurological and cognitive impairment seen, over and above that which would be expected from the underlying pathology alone. The epilepsy syndromes at high risk of this are a disparate group of condition...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-013-0041-6
更新日期:2013-03-01 00:00:00
abstract:BACKGROUND:The molecules that provide access to activated T cells in the CNS, including chemokines, have been considered to be a crucial step in the pathogenesis of multiple sclerosis (MS). AIMS:In this study, we investigated serial serum chemokine levels in patients with relapsing-remitting MS over 1 year and the ass...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11595060-000000000-00000
更新日期:2011-11-01 00:00:00
abstract::Smokeless tobacco (SLT) is used in a variety of forms throughout the world. Long-term SLT use is associated with adverse health consequences. Effective pharmacotherapies are needed to treat SLT users who want to achieve tobacco abstinence. In the current review, we discuss the pharmacological interventions identified ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11598450-000000000-00000
更新日期:2012-01-01 00:00:00
abstract:INTRODUCTION:The use of methylphenidate for the treatment of attention deficit-hyperactivity disorder (ADHD) has increased dramatically in the past decade in some countries in Europe and North America. In response to a public debate in Israel, several Knesset members introduced a legislative initiative that aims to lim...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/00023210-200317120-00005
更新日期:2003-01-01 00:00:00
abstract::Cognitive dysfunction is a major cause of disability in patients with multiple sclerosis (MS). The prevalence of cognitive dysfunction is estimated at 45 to 65%. Natural history studies suggest that once cognitive dysfunction develops in a patient with MS, it is not likely to remit. Unlike physical disability in MS, c...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200216070-00002
更新日期:2002-01-01 00:00:00
abstract::Levetiracetam (Keppra®, E Keppra®) is an established second-generation antiepileptic drug (AED). Worldwide, levetiracetam is most commonly approved as adjunctive treatment of partial-onset seizures with or without secondary generalization; other approved indications include monotherapy treatment of partial-onset seizu...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11208340-000000000-00000
更新日期:2011-10-01 00:00:00
abstract::The link between diabetes mellitus and Alzheimer's disease (AD) has been known for the last few decades. Since insulin and insulin receptors are known to be present in the brain, the downstream signalling as well as the effect of hyperinsulinemia have been extensively studied in both AD and Parkinson's disease. Glucag...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-015-0301-8
更新日期:2015-12-01 00:00:00
abstract::The issue of antipsychotic treatment during pregnancy is subject to substantial uncertainty and some controversy among healthcare providers, specifically pertaining to second-generation antipsychotics (SGAs) that are subject to a large gap in safety data during pregnancy compared with antidepressants. The amount of sa...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-018-0517-5
更新日期:2018-04-01 00:00:00
abstract:BACKGROUND:No head-to-head clinical trials have been published comparing guanfacine extended release (GXR) and atomoxetine (ATX): two nonstimulants approved for the treatment of attention-deficit/hyperactivity disorder (ADHD). However, other study designs or methods could be used to indirectly compare these two medicat...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.1007/s40263-013-0102-x
更新日期:2013-11-01 00:00:00
abstract::Friedreich ataxia (FA) is a progressive genetic neurological disorder associated with degeneration of the dorsal columns, spinocerebellar tracts and other regions of the nervous system. The disorder results from mutations in the gene referred to as FXN. Almost all mutations are expansions of an intronic GAA repeat in ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200923030-00003
更新日期:2009-01-01 00:00:00
abstract::L-Dopa-induced dyskinesias (LID) are the most common adverse effects of long-term dopaminergic therapy in Parkinson's disease (PD). However, the exact mechanisms underlying dyskinesia are still unclear. For a long time, nigrostriatal degeneration and pulsatile stimulation of striatal postsynaptic receptors have been h...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-014-0205-z
更新日期:2014-12-01 00:00:00
abstract::Antipsychotic polypharmacy refers to the co-prescription of more than one antipsychotic drug for an individual patient. Surveys of prescribing in psychiatric services internationally have identified the relatively frequent and consistent use of combined antipsychotics, usually for people with established schizophrenia...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11587810-000000000-00000
更新日期:2011-05-01 00:00:00
abstract::An explosion in antiepileptic drug (AED) therapy began in the 1990s with the licensing of 9 new chemical entities and more to come. Important differences between AEDs may not be detected by regulatory trials, which are designed to satisfy licensing requirements and often diverge considerably from everyday clinical pra...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200115010-00001
更新日期:2001-01-01 00:00:00
abstract::Oral fingolimod (Gilenya™), a sphingosine 1-phosphate (S1P) receptor agonist, is the first oral agent and the first in a novel class of disease-modifying therapies (DMTs) to be approved for use in the US for the treatment of relapsing forms of multiple sclerosis (MS). In the EU, fingolimod is approved for use as a sin...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/11207350-000000000-00000
更新日期:2011-08-01 00:00:00
abstract::Duloxetine (Cymbalta(R)) is a potent serotonin and noradrenaline (norepinephrine) reuptake inhibitor (SNRI) in the CNS. It is indicated for the treatment of generalized anxiety disorder (GAD) as well as other indications. In patients with GAD of at least moderate severity, oral duloxetine 60-120 mg once daily was effe...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.2165/00023210-200923060-00006
更新日期:2009-01-01 00:00:00
abstract:BACKGROUND:There are few data about the cost effectiveness of prophylactic medications for migraine. Clinical trials have shown several preventive agents to be useful in reducing the frequency of migraine attack while having tolerable side effects. OBJECTIVE:To compare the cost effectiveness of adding preventive treat...
journal_title:CNS drugs
pub_type: 杂志文章
doi:10.2165/11531180-000000000-00000
更新日期:2010-08-01 00:00:00
abstract::Methylene blue is a long-established drug with complex pharmacology and multiple clinical indications. Its diverse mechanisms of action are most likely responsible for the large variety of its clinical effects. Of interest to psychiatrists, methylene blue has antidepressant, anxiolytic, and neuroprotective properties ...
journal_title:CNS drugs
pub_type: 杂志文章,评审
doi:10.1007/s40263-019-00641-3
更新日期:2019-08-01 00:00:00